Subject(s)
Biotechnology/organization & administration , COVID-19 Vaccines , COVID-19/prevention & control , Drug Development/organization & administration , Pandemics/prevention & control , Biotechnology/economics , COVID-19/economics , COVID-19/epidemiology , Clinical Trials as Topic/economics , Clinical Trials as Topic/organization & administration , Cuba/epidemiology , Drug Development/economics , Humans , International Cooperation , Intersectoral Collaboration , Mass Vaccination/economics , Mass Vaccination/organization & administration , Pandemics/economicsSubject(s)
Biological Specimen Banks , Biotechnology , Nervous System Diseases , Neurosciences , Academic Medical Centers/organization & administration , Academic Medical Centers/statistics & numerical data , Biological Specimen Banks/organization & administration , Biological Specimen Banks/statistics & numerical data , Biotechnology/organization & administration , Biotechnology/statistics & numerical data , Humans , Nervous System Diseases/diagnosis , Nervous System Diseases/genetics , Neurosciences/organization & administration , Neurosciences/statistics & numerical data , Sri LankaABSTRACT
Neurotechnological devices are failing to deliver on their therapeutic promise because of the time it takes to translate them from bench to clinic. In this Perspective, we reflect on lessons learned from medical device successes and failures and consider how such lessons might shape a strategic vision for translating neurotechnologies in the future. We articulate how the intentional design and deployment of "scientific platforms," from the technology stack of hardware and software through the supporting ecosystem, could catalyze a new wave of innovation, discovery, and therapy. We also identify specific actions that could promote future neurotechnology roadmaps and industrial-academic-government collaborative activities. We believe that community-supported neurotechnology platforms will prove to be transformational in accelerating ideas from bench to bedside, maximizing scientific discovery and improving patient care.
Subject(s)
Biomedical Research/organization & administration , Biotechnology/organization & administration , Neurosciences/instrumentation , Neurosciences/organization & administration , Translational Research, Biomedical/organization & administration , Humans , Information Dissemination , Neurosciences/methodsABSTRACT
The ability to detect disease early and deliver precision therapy would be transformative for the treatment of human illnesses. To achieve these goals, biosensors that can pinpoint when and where diseases emerge are needed. Rapid advances in synthetic biology are enabling us to exploit the information-processing abilities of living cells to diagnose disease and then treat it in a controlled fashion. For example, living sensors could be designed to precisely sense disease biomarkers, such as by-products of inflammation, and to respond by delivering targeted therapeutics in situ. Here, we provide an overview of ongoing efforts in microbial biosensor design, highlight translational opportunities, and discuss challenges for enabling sense-and-respond precision medicines.
Subject(s)
Bacteria/metabolism , Biomedical Technology , Biosensing Techniques/methods , Synthetic Biology/methods , Bacteria/genetics , Biotechnology/organization & administration , Humans , Inflammation/diagnosis , Protein Processing, Post-TranslationalABSTRACT
The coronavirus disease 2019 (COVID-19) pandemic has presented some significant challenges to the scientific community. However, this has also offered opportunities for the pursuit of new scientific activities, and in particular for the field of biotechnology.
Subject(s)
Betacoronavirus/pathogenicity , Biomedical Research/organization & administration , Biotechnology/organization & administration , Coronavirus Infections/epidemiology , Education, Distance/organization & administration , Pandemics , Pneumonia, Viral/epidemiology , COVID-19 , Coronavirus Infections/psychology , Humans , Information Dissemination/ethics , Information Dissemination/methods , Mexico/epidemiology , Pneumonia, Viral/psychology , Public Health , SARS-CoV-2 , Social Networking , United States/epidemiologyABSTRACT
Process intensification has shown great potential to increase productivity and reduce costs in biomanufacturing. This case study describes the evolution of a manufacturing process from a conventional processing scheme at 1000-L scale (Process A, n = 5) to intensified processing schemes at both 1000-L (Process B, n = 8) and 2000-L scales (Process C, n = 3) for the production of a monoclonal antibody by a Chinese hamster ovary cell line. For the upstream part of the process, we implemented an intensified seed culture scheme to enhance cell densities at the seed culture step (N-1) prior to the production bioreactor (N) by using either enriched N-1 seed culture medium for Process B or by operating the N-1 step in perfusion mode for Process C. The increased final cell densities at the N-1 step allowed for much higher inoculation densities in the production bioreactor operated in fed-batch mode and substantially increased titers by 4-fold from Process A to B and 8-fold from Process A to C, while maintaining comparable final product quality. Multiple changes were made to intensify the downstream process to accommodate the increased titers. New high-capacity resins were implemented for the Protein A and anion exchange chromatography (AEX) steps, and the cation exchange chromatography (CEX) step was changed from bind-elute to flow-through mode for the streamlined Process B. Multi-column chromatography was developed for Protein A capture, and an integrated AEX-CEX pool-less polishing steps allowed semi-continuous Process C with increased productivity as well as reductions in resin requirements, buffer consumption, and processing times. A cost-of-goods analysis on consumables showed 6.7-10.1 fold cost reduction from the conventional Process A to the intensified Process C. The hybrid-intensified process described here is easy to implement in manufacturing and lays a good foundation to develop a fully continuous manufacturing with even higher productivity in the future.
Subject(s)
Antibodies, Monoclonal/metabolism , Bioreactors/economics , Biotechnology/organization & administration , Animals , Biotechnology/economics , CHO Cells , Cell Culture Techniques , Cell Proliferation , Costs and Cost Analysis , Cricetinae , Cricetulus , Efficiency , Humans , Inventions , Models, EconomicABSTRACT
Forty-three years after it was founded, with billions of dollars invested, the global biotech industry is still not positioned as a mature low-risk sector for the international investor com-munity. Despite the clear commercial success of a number of leading companies and overall growth of the industry's rev-enues, most biotech companies are not profi table and many fail to overcome the formidable barrier constituted by the high cost of the sector's research and development. However, over the last four years, visible signs of change have appeared, which could be harbingers of an approaching turning point in this trend.This article analyzes the historic background of the biotech in-dustry's business models and corporate structures, as well as their impact on the industry's fi nancial framework. It examines recent changes implemented by the sector's main actors-in-cluding young startups, venture capital funds and big pharma companies-to mitigate fi nancial risk associated with develop-ment of new biotechnology products.Finally, it discusses the challenges and opportunities that these tendencies entail for Cuban biotechnology development and proposes adoption of business policies more tolerant of the fi nancial risk inherent in this sector, as a condition for at-tracting venture capital. KEYWORDS Biotechnology, fund raising, risk management, entrepreneurship, Cuba.
Subject(s)
Biotechnology/economics , Industry/economics , Biotechnology/organization & administration , Commerce/economics , Commerce/organization & administration , Cuba , Financial Management/economics , Financial Management/organization & administration , Humans , Industry/organization & administration , Models, Organizational , Research Support as Topic/economics , Research Support as Topic/organization & administrationABSTRACT
The UK Industrial Biotechnology (IB) Strategy presents a consistent plan to develop the IB sector but fails to endorse an innovation process that allows for input from multiple publics. This could be disadvantageous for the bioeconomy: there are notable cases where negligence to address societal dimensions has caused innovation failure.
Subject(s)
Biotechnology , Research , Social Responsibility , Biotechnology/ethics , Biotechnology/organization & administration , Biotechnology/standards , Ethics, Research , Humans , Inventions/ethics , Inventions/standards , Research/organization & administration , Research/standards , United KingdomABSTRACT
The Industrial Revolution brought new economics and new epidemic patterns to the people, which formed the healthcare 1.0 that focused on public health solutions. The emergence of large production concept and technology brought healthcare to 2.0. Bigger hospitals and better medical education were established, and doctors were trained for specialty for better treatment quality. The size of computer shrunk. This allowed fast development of computer-based devices and information technology, leading the healthcare to 3.0. The initiation of smart medicine nowadays announces the arrival of healthcare 4.0 with new brain and new hands. It is an era of big revision of previous technologies, one of which is artificial intelligence which will lead humans to a new world that emphasizes more on advanced and continuous learnings.